Clinical decision support for oncologists that reasons like a trusted colleague, grounded only in champion-authored, cited knowledge. Ask the question; get the answer, the decision rule, and what's missing.
A large language model will answer any oncology question with total confidence, and no idea whether it's right. NCCN and ASCO move faster than anyone can read. What you actually want is a colleague who knows the evidence cold, tells you the decision rule, and admits what they'd need to know to be sure.
A thinking partner, not a search box. Three steps, the way you'd use a colleague.
Type or speak a real clinical question, like "metastatic NSCLC, EGFR exon 19 deletion, PS 1 — first-line?" No rigid syntax.
A specialist-grade answer grounded only in red-penned knowledge, with the decision rule and the specific data that would sharpen it.
You stay the decision-maker. It carries the evidence and the caveats, so the call is yours: faster, and better defended.
Real oncology questions, answered in the format our knowledge base speaks: answer → decision rule → what's missing → source.
For a sensitizing EGFR mutation (exon 19 deletion or L858R), a third-generation EGFR TKI such as osimertinib is preferred first-line over chemotherapy, including in CNS disease.FLAURA / NCCN
Decision ruleConfirm the actionable alteration on validated molecular testing before starting; targeted therapy precedes chemotherapy when a sensitizing driver is present.
Missing data: The exact variant, PD-L1, brain-metastasis status, performance status, and organ function change the choice.
Draw cultures and give an empiric anti-pseudomonal beta-lactam (cefepime or piperacillin-tazobactam) within the first hour, then risk-stratify with MASCC to choose inpatient IV versus selected outpatient oral therapy.IDSA / ASCO
Decision ruleAntibiotics first and fast, within 60 minutes; add MRSA or antifungal cover based on instability, catheters, or persistent fever.
Missing data: ANC, vital signs and sepsis features, source, catheter status, and prior colonization change the regimen.
All three answer questions. Only one is a specialist colleague whose every claim you can trace.
The waitlist isn't a marketing list. It's a founding cohort. Members shape the specialty, get in before anyone else, and lock the founding price for good.
Leave your name and work email. We'll reach out the moment clinical oncology opens — with your Founding Physician offer.
One email at launch. No spam, ever.
No. It's a physician-facing clinical decision-support companion — a thinking partner for your reasoning. It does not diagnose, does not treat, and gives no patient-facing advice. The clinical decision always stays with you.
Verified physicians only. Each specialty is led by a champion physician who red-penned its knowledge base, and 30+ specialties are built. Access is gated to licensed physicians.
Every answer is grounded only in champion-authored, cited knowledge — traceable, not hallucinated. It reasons like a colleague in your specialty, and always states the decision rule plus what data is missing, instead of a confident guess.
30+ specialties are built, each with its own specialist "soul" and cited knowledge base. Neurosurgery leads; cardiology, clinical oncology, emergency medicine and intensive care follow.
It's being built now. Waitlist members get first access and the Founding Physician offer: one free month plus 50% off the first three months, and a numbered founding badge.
This page collects only your name and email, for launch contact. In the product, clinical inputs are de-identified on-device; no patient data is stored on this marketing site.